score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable		Clinical evidence		Copy Number	BRAF	Amplification				0.0	0.0								Putatively Actionable	Vemurafenib	Targeted therapy	Amplification of BRAF may predict resistance to RAF inhibition.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631						0				BRAF Amplification		MEL-IPI_Pat17	MEL-IPI_Pat17-Tumor-SM-4DK1D	
Investigate Actionability - High	Guideline			Somatic Variant	MET	Splice Site		0.4716	422.0	0.0	0.0		Investigate Actionability - High	Crizotinib	Targeted therapy	Crizotinib is an available targeted agent with activity against MET exon 14 skipping variants in metastatic, NSCLC.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf												0				MET  (Splice Site)	0.0	MEL-IPI_Pat17	MEL-IPI_Pat17-Tumor-SM-4DK1D	MEL-IPI_Pat17-Normal-SM-4NFUJ
Investigate Actionability - Low	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Deletion	p.600_601VK>E	0.5824	546.0	0.0	0.0		Investigate Actionability - Low	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Investigate Actionability - Low	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability - Low	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.600_601VK>E (Deletion)	1.0	MEL-IPI_Pat17	MEL-IPI_Pat17-Tumor-SM-4DK1D	MEL-IPI_Pat17-Normal-SM-4NFUJ
Investigate Actionability - Low	Clinical evidence			Somatic Variant	MSH6	Missense	p.S314G	0.0086	582.0	0.0	0.0		Investigate Actionability - Low	Pembrolizumab	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596												0				MSH6 p.S314G (Missense)		MEL-IPI_Pat17	MEL-IPI_Pat17-Tumor-SM-4DK1D	MEL-IPI_Pat17-Normal-SM-4NFUJ
Investigate Actionability - Low	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.G129E	0.5512	283.0	0.0	0.0		Investigate Actionability - Low	AZD8186	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability - Low	Pembrolizumab	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202-16.	https://doi.org/10.1158/2159-8290.CD-15-0283	Investigate Actionability - Low	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0				PTEN p.G129E (Missense)	1.0	MEL-IPI_Pat17	MEL-IPI_Pat17-Tumor-SM-4DK1D	MEL-IPI_Pat17-Normal-SM-4NFUJ
Biologically Relevant				Somatic Variant	ROS1	Missense	p.K2N	0.3476	328.0	0.0	0.0																			0				ROS1 p.K2N (Missense)		MEL-IPI_Pat17	MEL-IPI_Pat17-Tumor-SM-4DK1D	MEL-IPI_Pat17-Normal-SM-4NFUJ
Biologically Relevant				Copy Number	EZH2	Amplification				0.0	0.0																			0				EZH2 Amplification		MEL-IPI_Pat17	MEL-IPI_Pat17-Tumor-SM-4DK1D	
Biologically Relevant				Mutational Signature	COSMIC Signature 7		0.787																							0				COSMIC Signature 7 (79%)		MEL-IPI_Pat17		
